◇◇新语丝(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)◇◇

举报江苏省扬州大学医学院院长史宏灿论文造假

　　作为一普通的科研工作者，最近看到国家自然科学基金委对于学术造假行为
的严惩，大快人心，对于学术造假应当是零容忍，最近偶然查询文献发现一奇怪
现象，经仔细查证，发现通讯作者为扬州大学医学院“史宏灿”，几乎同时在不
同的杂志发表了连题目和摘要都完全一样的文章，真是令人惊叹于他的胆气，不
但一稿多投而且一字不差同时发表，令人惊叹，此人在2006-2011先后获得3个
NSFC资助，其是否利于这2篇SCI文章进行了结题及其他不正当利益，网上搜索发
现这位近年来似乎在各种人才计划以及科研项目均获得不少，对于史宏灿发表的
其他论文，建议进行检查，不排除仍有此类现象甚至造假行为存在，下为2篇文
章的题目与摘要。

1. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1530-6.

Expression of multidrug resistance-related proteins p-glycoprotein, 
glutathione-s-transferases, topoisomerase-II and lung resistance 
protein in primary gastric cardiac adenocarcinoma.
Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K.

Department of Cardiothoracic Surgery, Clinical College Yangzhou 
University, Yangzhou 225001, Jiangsu Province, China. 
shihongcan@gmail.com.cn

Abstract
BACKGROUND/AIMS: Multidrug resistance (MDR) is closely correlated to 
an unfavorable prognosis in various human cancers. However, the 
clinical significance of the expression of MDR-related proteins 
p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), 
topoisomerase-II (Topo-II) and lung resistance protein (LRP) in 
primary gastric cardiac adenocarcinoma (PGCA) remains unclear. In this 
study, the total of the four kinds of MDR-related proteins mentioned 
above were detected by using immunohistochemistry and their clinical 
significance in chemoresistance were also investigated.

METHODOLOGY: This retrospective study included 69 resected specimens 
from patients with PGCA. The expression of PGP, GST-pi, Topo-II and 
LRP in formalin-fixed paraffin-embedded tissue sections was determined 
by a labelled streptavidin-biotin immunohistochemical technique, and 
the results were analyzed in correlation with clinicopathological data. 
None of these patients received chemotherapy prior to surgery.

RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and 
LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) 
were all higher than that of the normal tissues (0, 30%, 20% and 0, 
respectively, P<0.01). PGP expression in tumors that had metastasized 
was significantly more frequent than in tumors that had not 
metastasized (67.5% vs. 24.1%, P<0.01).The expression of PGP was 
closely related with clinicopathologic staging (staging 1/2 vs. 3/4, 
28.6% vs. 58.3%, P<0.05). No significant correlation was shown between 
PGP and increasing differentiated degree (40%, 42.4% and 61.5%, P>0.05). 
GST-pi expression status progressively increased with increasing 
differentiated degree (40%, 75.8% and 88.5%, P<0.05) and clinico 
pathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 83.3%, P<0.05). In 
addition, a significant positive correlation was also observed between 
GST-pi and lymphatic metastasis (with vs. without metastasis, 87.5% vs. 
58.6%, P<0.05). The expression of Topo-II was associated with 
increasing differentiated degree (33.3%, 69.7% and 80.7%, P<0.01). No 
significant differences with Topo-II expression was found in relation 
to the clinicopathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 72.9%, 
P>0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs. 
72.4%, P>0.05). Moreover, a significant difference with the expression 
of LRP was found in relation to the clinicopathologic stage (staging 
1/2 vs. 3/4, 38% vs. 66.6%, P<0.05), and lymphatic metastasis (with vs. 
without metastasis, 70.0% vs. 41.4%, P<0.05). Comparing the well, 
moderately and poorly differentiated cohort, a non-statistical 
increasing trend towards LRP expression status was noted (50.0%, 54.5% 
and 65.3%, respectively, P>0.05). Besides, the co-expression of all 
four tested MDR-related proteins also existed. The positive rates of 
co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi 
and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and 
LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0%, 26.1%, 7.24%, 
5.8%, respectively.

CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II and LRP are 
involved in multiple mechanisms of drug resistance in PGCA. Combined 
determination of PGP, GST-pi, Topo-II and LRP may be prospectively 
valuable for optimizing the chemotherapy regimes, developing high 
quality anti-cancer drugs, and further predicting the outcomes of 
those patients with PGCA.

PMID: 19102336 [PubMed – indexed for MEDLINE]

2. Cancer Invest. 2008 May;26(4):344-51.

Expression of multidrug-resistance-related proteins P-glycoprotein, 
glutathione-S-transferases, topoisomerase-II and lung resistance 
protein in primary gastric cardiac adenocarcinoma.
Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K.

Department of Cardiothoracic Surgery, Clinical College, Yangzhou 
University, Yangzhou, Jiangsu Province, China. shihongcan@gmail.com.cn

Abstract
AIM: Multidrug resistance (MDR) is closely correlated to an 
unfavorable prognosis in various human cancers. However, the clinical 
significance of the expression of MDR-related proteins p-glycoprotein 
(PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) 
and lung resistance protein (LRP) in primary gastric cardiac 
adenocarcinoma (PGCA) remains unclear. In this present study, the 
total of the four kinds of MDR-related proteins mentioned above were 
detected by using immunohistochemistry, and their clinical 
significance in chemoresistance were also investigated.

METHODS: This retrospective study included 69 resected specimens from 
patients with PGCA. The expression of PGP, GST-pi, Topo-II and LRP in 
formalin-fixed paraffin-embedded tissue sections was determined by a 
labelled streptavidin-biotin immunohistochemical technique, and the 
results were analyzed in correlation with clinicopathological data. 
None of these patients received chemotherapy prior to surgery.

RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and 
LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) 
were all higher than that of the normal tissues(0, 30%, 20% and 0, 
respectively, P < 0.01). PGP expression in tumors that had 
metastasized was significantly more frequent than in tumors that had 
not metastasized (67.5% vs 24.1%, P < 0.01). The expression of PGP was 
closely related with clinicopathologic staging (staging 1/2 vs 3/4, 
28.6% vs 58.3%, P < 0.05). No significant correlation was shown 
between PGP and increasing differentiated degree (40%, 42.4% and 61.5%, 
P > 0.05). GST-pi expression status progressively increased with 
increasing differentiated degree (40%, 75.8% and 88.5%, P < 0.05) and 
clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 83.3%, P < 0.05). 
In addition, a significant positive correlation was also observed 
between GST-pi and lymphatic metastasis (with vs. without metastasis, 
87.5% vs 58.6%, P < 0.05). The expression of Topo-II was associated 
with increasing differentiated degree (33.3%, 69.7 and 80.7%, P < 0.01). 
No significant differences with Topo-II expression were found in 
relation to the clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 
72.9%, P > 0.05) and lymphatic metastasis (with vs. without metastasis, 
65.0% vs 72.4%, P > 0.05). Moreover, a significant difference with the 
expression of LRP was found in relation to the clinicopathologic stage 
(staging 1/2 vs 3/4, 38% vs 66.6%, P < 0.05), and lymphatic metastasis 
(with vs without metastasis, 70.0% vs 41.4%, P < 0.05). Comparing the 
well, moderately and poorly differentiated cohort, a non-statistical 
increasing trend towards LRP expression status was noted (50.0%, 54.5% 
and 65.3%, respectively, P > 0.05). Besides, the co-expression of all 
four tested MDR-related proteins also existed. The positive rates of 
co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi 
and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and 
LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0, 26.1, 7.24, 5.8, 
respectively.

CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II alpha and LRP 
are involved in multiple mechanisms of drug resistance in PGCA. 
Combined determination of PGP, GST-pi, Topo-II and LRP may be 
prospectively valuable for optimizing the chemotherapy regimes, 
developing high quality anti-cancer drugs, and further predicting the 
outcomes of those patients with PGCA.

PMID: 18443954 [PubMed – indexed for MEDLINE]

(XYS20130806)

◇◇新语丝(www.xys.org)(xys7.dxiong.com)(xys.ebookdiy.com)(xys2.dropin.org)◇◇